Immunomodulatory Arming Factors—The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules

Abstract excerpt

The dogma of engineering oncolytic viral vectors has shifted from emphasizing the viral lysis of individual cancer cells to the recruitment and coordination of the adaptive immune system to clear the tumor. To accomplish this, researchers have been adding several classes of transgenes to their preferred viral platforms. The most prevalent of these include antibodies and targeting moieties, interleukins and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Research and Treatments
• Share to CAR-T cell therapy research
• Share to Virus-based gene therapy research